Results 31 to 40 of about 3,014 (182)

Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs

, 2020
The development of multidrug resistance (MDR) in cancer patients, which is often associated with the overexpression of ABCB1 (MDR1, P-glycoprotein) in cancer cells, remains a significant problem in cancer chemotherapy. ABCB1 is one of the major adenosine
Yu-Shan Wu, Chung-Pu Wu, Lang-Cheng Hung, Shun-Ping Wang, Tai-Ho Hung, Yu-Tzu Chang, Yang-Hui Huang, Sung-Han Hsiao, Yi-Jou Yu   +8 more
core   +1 more source

Precision medicine: Sustained response to erdafitinib in FGFR2‐mutant, multiply recurrent ameloblastoma

Cancer Reports, 2022
Background Ameloblastoma imposes significant morbidity and high‐recurrence rates following surgery and radiation therapy. Although 89% of cases harbor oncogenic mutations, the role of targeted therapy is undefined.
Katherine A. Lawson‐Michod, Christopher H. Le, Ghassan Tranesh, Penelope C. Thomas, Julie E. Bauman   +4 more
doaj   +1 more source

Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis

Frontiers in Oncology, 2023
ObjectiveThis review aimed to comprehensively analyze the safety and efficacy of erdafitinib in treating advanced and metastatic urothelial carcinoma and other solid tumors.MethodsPubMed, Embase, and ClinicalTrials.gov were searched until 10 February ...
Xinyi Zheng, Hang Wang, Junyue Deng, Minghe Yao, Xiuhe Zou, Fan Zhang, Xuelei Ma   +6 more
doaj   +1 more source

Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain FGFR genetic alterations

, 2022
FGFR inhibitors represent a new and promising therapeutic approach to urothelial cancer (UC). Erdafitinib (Balversa©) was the first FGFR inhibitor approved for the treatment of metastatic UC, showing proper pharmacological activity and a consistent ...
Giannatempo, Patrizia, Franza, Andrea, Cosmai, Laura, Pirovano, Marta   +3 more
core   +1 more source

Management of Fibroblast Growth Factor Inhibitor Treatment–emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

European Urology Open Science, 2023
Background: Erdafitinib is indicated for the treatment of adults with locally advanced/metastatic urothelial carcinoma and susceptible FGFR3/2 alterations progressing on/after one or more lines of prior platinum-based chemotherapy.
Arlene O. Siefker-Radtke, Andrea Necchi, Se Hoon Park, Jesús García-Donas, Robert A. Huddart, Earle F. Burgess, Mark T. Fleming, Arash Rezazadeh Kalebasty, Begoña Mellado, Sergei Varlamov, Monika Joshi, Ignacio Duran, Scott T. Tagawa, Yousef Zakharia, Keqin Qi, Sydney Akapame, Spyros Triantos, Anne O'Hagan, Yohann Loriot   +18 more
doaj   +1 more source

Identifying fibroblast growth factor receptor genetic alterations using RNA‐based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment

The Journal of Pathology: Clinical Research, 2020
Erdafitinib, a pan‐fibroblast growth factor receptor (FGFR) inhibitor received accelerated approval from the US Food and Drug Administration (FDA) for locally advanced or metastatic urothelial carcinoma (mUC) in adult patients with specific FGFR3/2 ...
Songbai Wang, Mike Burgess, Christopher Major, Alistair English, Maranna Sweeney, Arndt Hartmann   +5 more
doaj   +1 more source

Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis

Frontiers in Oncology, 2023
BackgroundErdafitinib, a fibroblast growth factor receptor (FGFR) inhibitor is a standard post chemotherapy advanced treatment line for metastatic urothelial carcinoma harboring FGFR2/3 genomic alterations.
Keren Rouvinov, Keren Rouvinov, Eran Levanon, Avivit Peer, Michal Sarfaty, David Sarid, Victoria Neiman, Eduard Grikshtas, Eli Rosenbaum, Igal Kushnir, Barak Talmor, Michael Friger, Yonaton Zarbiv, Eli Gez, Hadas Dresler, Walid Shalata, Amichay Meirovitz, Amichay Meirovitz, Noa Shani Shrem, Alexander Yakobson, Alexander Yakobson, Wilmosh Mermershtain, Daniel Keizman   +22 more
doaj   +1 more source

Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and <i>FGFR</i> Alterations: Final Results From the Phase II NORSE Study. [PDF]

J Clin Oncol
PURPOSE: First-line treatment options for cisplatin-ineligible patients with metastatic urothelial cancer (mUC) are limited. We conducted a phase II study of erdafitinib, alone or with cetrelimab, in FGFR-altered mUC.
Loriot Y, Powles T, Moreno V, Kang TW, Cicin I, Girvin A, Akapame S, O'Hagan A, Zhu W, Tammaro M, Thomas S, Triantos S, Siefker-Radtke AO.   +12 more
europepmc   +2 more sources

Reversible Retinopathy Associated with Fibroblast Growth Factor Receptor Inhibitor

Case Reports in Ophthalmology, 2022
We present a case of reversible, pseudovitelliform lesions while a patient was taking pembrolizumab (PDL-1 inhibitor) and erdafitinib (pan-fibroblast growth factor receptor inhibitor) outside of clinical trial protocols. A 61-year-old patient with 3 days
Saagar N. Patel, Mona L. Camacci, Esther M. Bowie   +2 more
doaj   +1 more source

Erdafitinib-associated retinal alterations and rapid onset bilateral white cataracts

American Journal of Ophthalmology Case Reports
Purpose: This report aims to highlight the wide spectrum of ophthalmic adverse events associated with erdafitinib, a fibroblast growth factor inhibitor that blocks activation of the mitogen-activated protein kinase kinase (MAPK/MEK) cascade.
Antoine G. Sassine, Yavuz Cakir, Lyndsey Della Vecchia, Justis P. Ehlers   +3 more
doaj   +1 more source